To include your compound in the COVID-19 Resource Center, submit it here.

Pfizer ending discovery, early neuroscience program

Pfizer Inc. (NYSE:PFE) said Friday it will terminate its discovery and early development neuroscience programs as a result of a "recent comprehensive review." The pharma estimates

Read the full 261 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE